Related Experiment Video
Updated: May 25, 2026
Detection and Quantification of Calcitonin Gene-Related Peptide (CGRP) in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
Published on: June 16, 2023
Limitations of Chromogranin A in clinical practice
Vincenzo Marotta1, Vincenzo Nuzzo, Teresa Ferrara
1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy.
Context:
Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool.
Methods:
Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay.
Results:
The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions.
Conclusion:
Serum CgA is not helpful for the first-line diagnosis of NEN.
